MX2017010595A - Métodos, composiciones, y equipos para tratamiento de cáncer. - Google Patents

Métodos, composiciones, y equipos para tratamiento de cáncer.

Info

Publication number
MX2017010595A
MX2017010595A MX2017010595A MX2017010595A MX2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A
Authority
MX
Mexico
Prior art keywords
kits
compositions
cancer
treatment
methods
Prior art date
Application number
MX2017010595A
Other languages
English (en)
Spanish (es)
Inventor
Holash Jocelyn
Lau Stephen
Original Assignee
Bioclin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioclin Therapeutics Inc filed Critical Bioclin Therapeutics Inc
Publication of MX2017010595A publication Critical patent/MX2017010595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017010595A 2015-02-19 2016-02-19 Métodos, composiciones, y equipos para tratamiento de cáncer. MX2017010595A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118350P 2015-02-19 2015-02-19
US201562150235P 2015-04-20 2015-04-20
PCT/US2016/018634 WO2016134234A1 (en) 2015-02-19 2016-02-19 Methods, compositions, and kits for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2017010595A true MX2017010595A (es) 2018-11-12

Family

ID=56689191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010595A MX2017010595A (es) 2015-02-19 2016-02-19 Métodos, composiciones, y equipos para tratamiento de cáncer.

Country Status (12)

Country Link
US (1) US20160243228A1 (enExample)
EP (1) EP3258966A4 (enExample)
JP (2) JP6774421B2 (enExample)
KR (1) KR20170137717A (enExample)
CN (1) CN107635583A (enExample)
AU (2) AU2016219917B2 (enExample)
BR (1) BR112017017700A2 (enExample)
CA (1) CA2976638A1 (enExample)
IL (1) IL253979B (enExample)
MX (1) MX2017010595A (enExample)
SG (1) SG11201706727XA (enExample)
WO (1) WO2016134234A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3702371B1 (en) 2009-03-25 2022-11-02 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
WO2017104739A1 (ja) 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
KR20200026787A (ko) * 2017-02-06 2020-03-11 레이니어 테라퓨틱스, 인크. 암 치료를 위한 방법, 조성물, 및 키트
CN108440673B (zh) * 2018-04-08 2021-08-17 海南医学院 Fc融合蛋白PD1/FGFR1及其应用
US20200277387A1 (en) * 2019-03-01 2020-09-03 Rainier Therapeutics, Inc. Methods and compositions for treating cancer
KR20220016803A (ko) * 2019-06-03 2022-02-10 퓨전 파마슈티칼즈 인크. 암을 치료하기 위한 방법 및 조성물
JP7709959B2 (ja) * 2019-09-26 2025-07-17 ヤンセン ファーマシューティカ エヌ．ベー． 連続的な治療設定における免疫チェックポイント阻害剤に対する患者の応答を高めるためのｆｇｆｒ遺伝子改変癌におけるｆｇｆｒ阻害剤の使用
CA3176617A1 (en) * 2020-03-23 2021-09-30 Fusion Pharmaceuticals Inc. Fgfr3-targeted radioimmunoconjugates and uses thereof
AU2021327387A1 (en) 2020-08-21 2023-05-04 Genzyme Corporation Fgfr3 antibodies and methods of use
TW202233185A (zh) * 2020-10-28 2022-09-01 日商衛材R&D企管股份有限公司 腫瘤治療用醫藥組合物
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
EP3702371B1 (en) * 2009-03-25 2022-11-02 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
WO2012088266A2 (en) * 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014018841A1 (en) * 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
AU2014290069B2 (en) * 2013-07-16 2019-01-03 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

Also Published As

Publication number Publication date
EP3258966A1 (en) 2017-12-27
EP3258966A4 (en) 2018-07-25
AU2022200196B2 (en) 2025-04-10
KR20170137717A (ko) 2017-12-13
SG11201706727XA (en) 2017-09-28
JP2021020909A (ja) 2021-02-18
IL253979B (en) 2021-06-30
AU2016219917A1 (en) 2017-09-07
US20160243228A1 (en) 2016-08-25
JP7122357B2 (ja) 2022-08-19
JP6774421B2 (ja) 2020-10-21
NZ735243A (en) 2024-11-29
AU2022200196A1 (en) 2022-02-10
CN107635583A (zh) 2018-01-26
JP2018507220A (ja) 2018-03-15
BR112017017700A2 (pt) 2018-07-31
IL253979A0 (en) 2017-10-31
CA2976638A1 (en) 2016-08-25
AU2016219917B2 (en) 2021-12-16
WO2016134234A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
MX2020008404A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
IL280158A (en) Methods of treating cancer with the PI3K inhibitor, GDC-0077
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
PH12016501550B1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
GEAP202014670A (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
AU2016263598A8 (en) Methods and kits for treating depression
PH12015502091A1 (en) Cdc7 inhibitors
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2021006326A (es) Inhibidores de pcna.
IL268163A (en) Methods, compositions, and kits for treatment of cancer
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
PH12017501879A1 (en) Methods for treating cancer
MX388409B (es) Composiciones y metodos para tratar canceres.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
PH12017501880A1 (en) Methods for treating cancer
MX2015013021A (es) 5-bromo-indirrubinas.
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
PH12016501838A1 (en) Compounds and their methods of use